Diabetes mellitus, glycemic control, and risk of atrial fibrillation - PubMed (original) (raw)
Diabetes mellitus, glycemic control, and risk of atrial fibrillation
Sascha Dublin et al. J Gen Intern Med. 2010 Aug.
Abstract
Background: Diabetes may be an independent risk factor for atrial fibrillation. However, results from prior studies are in conflict, and no study has examined diabetes duration or glycemic control.
Objective: To examine the association of diabetes with risk of atrial fibrillation and to describe risk according to diabetes duration and glycemic control.
Design: A population-based case-control study.
Participants: Within a large, integrated healthcare delivery system, we identified 1,410 people with newly-recognized atrial fibrillation from ICD-9 codes and validated cases by review of medical records. 2,203 controls without atrial fibrillation were selected from enrollment lists, stratified on age, sex, hypertension, and calendar year.
Main measures: Information on atrial fibrillation, diabetes and other characteristics came from medical records. Diabetes was defined based on physician diagnoses recorded in the medical record, and pharmacologically treated diabetes was defined as receiving antihyperglycemic medications. Information about hemoglobin A1c levels came from computerized laboratory data.
Key results: Among people with atrial fibrillation, 252/1410 (17.9%) had pharmacologically treated diabetes compared to 311/2203 (14.1%) of controls. The adjusted OR for atrial fibrillation was 1.40 (95% CI 1.15-1.71) for people with treated diabetes compared to those without diabetes. Among those with treated diabetes, the risk of developing atrial fibrillation was 3% higher for each additional year of diabetes duration (95% CI 1-6%). Compared to people without diabetes, the adjusted OR for people with treated diabetes with average hemoglobin A1c <or=7 was 1.06 (95% CI 0.74-1.51); for A1c >7 but <or=8, 1.48 (1.09-2.01); for A1c >8 but <or=9, 1.46 (1.02-2.08); and for A1c >9, 1.96 (1.22-3.14).
Conclusions: Diabetes was associated with higher risk of developing atrial fibrillation, and risk was higher with longer duration of treated diabetes and worse glycemic control. Future research should identify and test approaches to reduce the risk of atrial fibrillation in people with diabetes.
Figures
Figure 1
Risk of newly-recognized atrial fibrillation by duration of treated diabetes. The diamond represents the adjusted OR and the vertical line, the 95% CI. ORs are adjusted for age, sex, calendar year, treated hypertension, and body mass index. People with no history of diabetes are the referent group.
Figure 2
Risk of newly-recognized atrial fibrillation by average level of hemoglobin A1c. The diamond represents the adjusted OR and the vertical line, the 95% CI. ORs are adjusted for age, sex, calendar year, treated hypertension, and body mass index. People with no history of diabetes are the referent group.
Similar articles
- Glycemic Status and Thromboembolic Risk in Patients With Atrial Fibrillation and Type 2 Diabetes Mellitus: A Danish Cohort Study.
Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GYH, Jensen MB. Fangel MV, et al. Circ Arrhythm Electrophysiol. 2019 May;12(5):e007030. doi: 10.1161/CIRCEP.118.007030. Circ Arrhythm Electrophysiol. 2019. PMID: 30995869 - A Multicenter Real-Life Study on the Effect of Flash Glucose Monitoring on Glycemic Control in Patients with Type 1 and Type 2 Diabetes.
Anjana RM, Kesavadev J, Neeta D, Tiwaskar M, Pradeepa R, Jebarani S, Thangamani S, Sastry NG, Brijendra Kumar S, Ramu M, Gupta PPK, Vignesh J, Chandru S, Kayalvizhi S, Jagdish PS, Uthra SCB, Lovelena M, Jyoti S, Suguna Priya S, Kannan A, Mohan V, Unnikrishnan R. Anjana RM, et al. Diabetes Technol Ther. 2017 Sep;19(9):533-540. Diabetes Technol Ther. 2017. PMID: 28930495 - Management and prognosis of atrial fibrillation in the diabetic patient.
Pallisgaard JL, Lindhardt TB, Olesen JB, Hansen ML, Carlson N, Gislason GH. Pallisgaard JL, et al. Expert Rev Cardiovasc Ther. 2015 Jun;13(6):643-51. doi: 10.1586/14779072.2015.1043892. Expert Rev Cardiovasc Ther. 2015. PMID: 26000562 Review. - Diabetes and Stroke: What Are the Connections?
Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Mosenzon O, et al. J Stroke. 2023 Jan;25(1):26-38. doi: 10.5853/jos.2022.02306. Epub 2023 Jan 3. J Stroke. 2023. PMID: 36592968 Free PMC article. Review.
Cited by
- Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions.
Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik RA. Asghar O, et al. Curr Cardiol Rev. 2012 Nov;8(4):253-64. doi: 10.2174/157340312803760749. Curr Cardiol Rev. 2012. PMID: 22920475 Free PMC article. Review. - Acute hyperglycaemia is not associated with the development of atrial fibrillation in healthy pigs.
Manninger M, Zweiker D, Dobrovnik M, van Hunnik A, Rohrer U, Zirngast B, Herbst V, Maechler H, Schotten U, Zirlik A, Scherr D. Manninger M, et al. Sci Rep. 2020 Jul 17;10(1):11881. doi: 10.1038/s41598-020-68897-0. Sci Rep. 2020. PMID: 32681085 Free PMC article. - Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes.
Polina I, Jansen HJ, Li T, Moghtadaei M, Bohne LJ, Liu Y, Krishnaswamy P, Egom EE, Belke DD, Rafferty SA, Ezeani M, Gillis AM, Rose RA. Polina I, et al. Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):7990-8000. doi: 10.1073/pnas.1914853117. Epub 2020 Mar 20. Proc Natl Acad Sci U S A. 2020. PMID: 32198206 Free PMC article. - Beyond Ablation in Atrial Fibrillation: 10 Steps to Better Control.
Hynes M. Hynes M. Am J Lifestyle Med. 2020 Jul 26;15(4):434-440. doi: 10.1177/1559827620943326. eCollection 2021 Jul-Aug. Am J Lifestyle Med. 2020. PMID: 34366742 Free PMC article. Review. - The association between insulin resistance and atrial fibrillation: A cross-sectional analysis from SPRINT (Systolic Blood Pressure Intervention Trial).
Cho ME, Craven TE, Cheung AK, Glasser SP, Rahman M, Soliman EZ, Stafford RS, Johnson KC, Bates JT, Burgner A, Taylor AA, Tamariz L, Tang R, Beddhu S; SPRINT Study Research Group. Cho ME, et al. J Clin Hypertens (Greenwich). 2017 Nov;19(11):1152-1161. doi: 10.1111/jch.13062. Epub 2017 Sep 3. J Clin Hypertens (Greenwich). 2017. PMID: 28866864 Free PMC article. Clinical Trial.
References
- Bluher M, Fasshauer M, Tonjes A, Kratzsch J, Schon MR, Paschke R. Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism. Exp Clin Endocrinol Diabetes. 2005;113:534–7. doi: 10.1055/s-2005-872851. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K23 AG028954/AG/NIA NIH HHS/United States
- HL 68986/HL/NHLBI NIH HHS/United States
- K23AG028954/AG/NIA NIH HHS/United States
- R01 HL068986/HL/NHLBI NIH HHS/United States
- HL 73410/HL/NHLBI NIH HHS/United States
- K23 AG028954-03/AG/NIA NIH HHS/United States
- R01 HL043201/HL/NHLBI NIH HHS/United States
- R01 HL043201-13/HL/NHLBI NIH HHS/United States
- R01 HL073410/HL/NHLBI NIH HHS/United States
- R01 HL068986-04/HL/NHLBI NIH HHS/United States
- R01 HL073410-04/HL/NHLBI NIH HHS/United States
- R01 HL068639/HL/NHLBI NIH HHS/United States
- HL 43201/HL/NHLBI NIH HHS/United States
- HL 68639/HL/NHLBI NIH HHS/United States
- R01 HL068639-04/HL/NHLBI NIH HHS/United States